Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


RAND Report Recommends Case-Control Ephedra Study Look At AE Risk

This article was originally published in The Tan Sheet

Executive Summary

A case-control study examining the risk of serious adverse events related to the use of ephedra and ephedrine alkaloid-containing dietary supplements would fill a vital gap in the current body of research on the supplement ingredient, the RAND report states

Related Content

NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says
RAND Report Author’s Comments Show Bias, Ephedra Education Council Says
AERs Can Prove Causality – FDA Comments On GAO Ephedra Report
Ephedra Safety Risk Evidence Sufficient For Market Ban – Rep. Waxman
Ephedra Case-Control Study Supported By NCCAM Advisory Council
Ephedra Athletic Performance Claims Targeted In FDA Warning Letters
Ephedra “Black Box” Warning Considered By FDA
AHRQ Ephedra Evidence Report Targeted For August 2002 Release
PPA Increases Hemorrhagic Stroke Risk - Yale Study
PPA Increases Hemorrhagic Stroke Risk - Yale Study





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts